A significant number, around 20%, of melanoma patients harboring BRAF V600E mutation show disease progression early after beginning targeted therapy treatment, indicating the presence of intrinsic resistance in a proportion of melanoma cells within the tumor. The gene discussed is BRAF; the disease is neoplasm.